top
Please input keywords
Order
*Country
United States
China
France
Germany
Netherlands
United Kingdom
Japan
South Korea
Israel
Australia
Hong Kong, China
New Zealand
Russia
Singapore
Taiwan, China
India
Aland Islands
Albania
Algeria
American Samoa
Andorra
Angola
Anguilla
Antarctica
Antigua & Barbuda
Argentina
Armenia
Aruba
Ascension Island
Austria
Azerbaijan
Bahamas
Bahrain
Bangladesh
Barbados
Belarus
Belgium
Belize
Benin
Bermuda
Bhutan
Bolivia
Bosnia & Herzegovina
Botswana
Brazil
British Indian Ocean Territory
British Virgin Islands
Brunei
Bulgaria
Burkina Faso
Burundi
Cambodia
Cameroon
Canada
Canary Islands
Cape Verde
Caribbean Netherlands
Cayman Islands
Central African Republic
Ceuta & Melilla
Chad
Chile
Christmas Island
Cocos (Keeling) Islands
Colombia
Comoros
Congo - Brazzaville
Congo - Kinshasa
Cook Islands
Costa Rica
Côte d’Ivoire
Croatia
Cuba
Curaçao
Cyprus
Czechia
Denmark
Diego Garcia
Djibouti
Dominica
Dominican Republic
Ecuador
Egypt
El Salvador
Equatorial Guinea
Eritrea
Estonia
Ethiopia
Falkland Islands
Faroe Islands
Fiji
Finland
French Guiana
French Polynesia
French Southern Territories
Gabon
Gambia
Georgia
Ghana
Gibraltar
Greece
Greenland
Grenada
Guadeloupe
Guam
Guatemala
Guernsey
Guinea
Guinea-Bissau
Guyana
Haiti
Honduras
Hungary
Iceland
Indonesia
Iran
Iraq
Ireland
Isle of Man
Italy
Jamaica
Jersey
Jordan
Kazakhstan
Kenya
Kiribati
Kosovo
Kuwait
Kyrgyzstan
Laos
Latvia
Lebanon
Lesotho
Liberia
Libya
Liechtenstein
Lithuania
Luxembourg
Macau, China
Macedonia
Madagascar
Malawi
Malaysia
Maldives
Mali
Malta
Marshall Islands
Martinique
Mauritania
Mauritius
Mayotte
Mexico
Micronesia
Moldova
Monaco
Mongolia
Montenegro
Montserrat
Morocco
Mozambique
Myanmar (Burma)
Namibia
Nauru
Nepal
New Caledonia
Nicaragua
Niger
Nigeria
Niue
Norfolk Island
North Korea
Northern Mariana Islands
Norway
Oman
Pakistan
Palau
Palestinian Territories
Panama
Papua New Guinea
Paraguay
Peru
Philippines
Pitcairn Islands
Poland
Portugal
Puerto Rico
Qatar
Réunion
Romania
Rwanda
Samoa
San Marino
São Tomé & Príncipe
Saudi Arabia
Senegal
Serbia
Seychelles
Sierra Leone
Sint Maarten
Slovakia
Slovenia
Solomon Islands
Somalia
South Africa
South Georgia & South Sandwich Islands
South Sudan
Spain
Sri Lanka
St. Barthélemy
St. Helena
St. Kitts & Nevis
St. Lucia
St. Martin
St. Pierre & Miquelon
St. Vincent & Grenadines
Sudan
Suriname
Svalbard & Jan Mayen
Swaziland
Sweden
Switzerland
Syria
Tajikistan
Tanzania
Thailand
Timor-Leste
Togo
Tokelau
Tonga
Trinidad & Tobago
Tristan da Cunha
Tunisia
Turkey
Turkmenistan
Turks & Caicos Islands
Tuvalu
U.S. Outlying Islands
U.S. Virgin Islands
Uganda
Ukraine
United Arab Emirates
United Nations
Uruguay
Uzbekistan
Vanuatu
Vatican City
Venezuela
Vietnam
Wallis & Futuna
Western Sahara
Yemen
Zambia
Zimbabwe
*Province
*City
*Name
*Telephone
*Company
*Position
*Email
*Verification code
*Verification Code
B-hIL11RA mice
Strain Name
C57BL/6-Il11ra1tm1(IL11RA)Bcgen/Bcgen 
Common Name  B-hIL11RA mice
Background C57BL/6 Catalog number 110879
Related Genes 
interleukin 11 receptor, alpha chain 1

mRNA expression analysis


Strain specific analysis of IL11RA gene expression in wild-type mice and B-hIL11RA mice by RT-PCR.

Mouse Il11ra1 mRNA was detectable in liver of wild-type mice (+/+). Human IL11RA mRNA was detectable only in homozygous B-hIL11RA but not in wild-type mice.


Protein expression analysis




Strain specific IL11RA expression analysis in homozygous B-hIL11RA mice by western blot.

Tissue was collected from wild-type C57BL/6 mice (+/+) and homozygous B-hIL11RA mice (H/H), and analyzed by western blot with anti-IL11RA antibody. Mouse IL11RA1 and human IL11RA were detectable in wild type mice and homozygous B-hIL11RA mice, as the antibody is crossly reactive with IL11RA in human and mice. Mice IL11RA1 and human IL11RA were not detectable in kidney, which might be because of low protein levels compared with liver.

In vivo efficacy of anti-human IL11RA antibody with APAP-induced liver damage in B-hIL11RA mice


from clipboard


Reduction in APAP-induced liver damage with anti-IL11RA in male B-hIL11RA mice.(A) Schematic showing therapeutic dosing of APAP-injured mice. B-hIL11RA mice (male, 8 weeks, n=5) treated with PBS/anti-hIL11RA (in house, 15 mg/kg) were fasted overnight and inducted with APAP(400 mg/kg) for 24 h. Blood and liver tissue were collected for analysis. (B) Serum levels of ALT and AST were reduced in the anti-hIL11RA antibody-treated male mice group compared to the control. Values are expressed as mean ± SD. *p<0.05. 

In vivo efficacy of anti-human IL11RA antibody with APAP-induced liver damage in B-hIL11RA mice

from clipboard


Reduction in APAP-induced liver damage with anti-IL11RA in male B-hIL11RA mice.(A) Representative H&E-stained liver images (representative dataset from n = 5 per group). (B) Statistical analysis of necrosis area(% of total area). Values are expressed as mean ± SD. *p<0.05. 

In vivo efficacy of anti-human IL11RA antibody with APAP-induced liver damage in B-hIL11RA mice

from clipboard


Reduction in APAP-induced liver damage with anti-IL11RA in male B-hIL11RA mice.(A) Representative TUNEL-stained liver images (representative dataset from n=5 per group). (B) Statistical analysis of TUNEL positive cells(% of total cells). Values are expressed as mean ± SD. *p<0.05.